Adverum Biotechnologies Announces Upcoming Data Presentations at ARVO 2022
April 19, 2022 18:00 ET
|
Adverum Biotechnologies, Inc.
REDWOOD CITY, Calif., April 19, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare...
Adverum Biotechnologies Proceeds with IND Amendment for ADVM-022 Phase 2 Trial in Wet AMD After Receiving Requested Type C Meeting Feedback from the FDA
April 06, 2022 16:05 ET
|
Adverum Biotechnologies, Inc.
REDWOOD CITY, Calif., April 06, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare...
Adverum Biotechnologies Reports Fourth Quarter and Full Year 2021 Financial Results
March 29, 2022 16:05 ET
|
Adverum Biotechnologies, Inc.
REDWOOD CITY, Calif., March 29, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare...
Adverum Appoints Rabia Gurses Ozden, M.D. and Soo J. Hong, M.B.A., to Board of Directors
March 17, 2022 16:05 ET
|
Adverum Biotechnologies, Inc.
REDWOOD CITY, Calif., March 17, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare...
Adverum Biotechnologies to Participate in the 42nd Annual Cowen Healthcare Conference
February 28, 2022 08:00 ET
|
Adverum Biotechnologies, Inc.
REDWOOD CITY, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases,...
Adverum Biotechnologies Appoints Richard Beckman M.D. as Chief Medical Officer
February 07, 2022 16:05 ET
|
Adverum Biotechnologies, Inc.
- Dr. Beckman, a board-certified ophthalmologist, brings 30 years of experience in ophthalmology, drug development and retinal diseases including wet age-related macular degeneration - REDWOOD CITY,...
Adverum Biotechnologies Appoints Star Seyedkazemi, Pharm.D. as Chief Development Officer
January 06, 2022 16:05 ET
|
Adverum Biotechnologies, Inc.
REDWOOD CITY, Calif., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases,...
Adverum Biotechnologies Provides ADVM-022 Development Update and Anticipated Corporate Milestones for 2022
December 21, 2021 08:00 ET
|
Adverum Biotechnologies, Inc.
- Finalizing Two-Dose Study Design for Phase 2 Trial of ADVM-022 in Wet AMDwith Intention to Dose First Patient in Q32022 - - Anticipates Near-term Hires to Further Strengthen Executive Team - -...
Adverum Biotechnologies Appoints Rupert D’Souza, Ph.D., M.B.A. as Chief Financial Officer
December 06, 2021 09:00 ET
|
Adverum Biotechnologies, Inc.
REDWOOD CITY, Calif., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases,...
Adverum Reports Third Quarter 2021 Results
November 04, 2021 16:05 ET
|
Adverum Biotechnologies, Inc.
REDWOOD CITY, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases,...